Your Heart.
Your Data. Your Cure.

Reinventing Personalized Medicine for Heart Disease

Unmet Medical Need

Lifetime risk of atrial fibrillation is 1 in 3
over age 45 and its prevalence
continues to increase globally

Prevalence

12M AF Patients in the US

50M AF Patients Worldwide

Risks

5x Higher stroke risk

Decreased quality of life

Higher risk of heart failure
& other complications

Leading cause
of hospitalizations

Market Opportunity

Antiarrhythmic Drugs

Effective antiarrhythmic drugs for AF exist, but narrow therapeutic window

Patients must be admitted to the hospital for 3 days when starting certain drugs

Many patients and doctors avoid these drugs due to hospitalization burden

The winning product isn't always the strongest molecule. It is the one that reliably reaches the window.

Founder & CEO

David Strauss, MD/PhD

14+ years at the FDA
9Y FDA Center for Drugs
5Y FDA Center for Devices
1Y FDA Acting Chief Scientist

The Old Way

One Size Fits All Dosing
Variability among patients in benefit-risk
Larger trials required to demonstrate efficacy

Model-Informed Precision Dosing at Scale

Scale to All Classes of AF Drugs for Holistic Patient Management at Home

Model-Informed Precision Dosing Flow Diagram

Our Way

Model Informed Precision Dosing
Smaller, faster clinical trials to demonstrate efficacy
and fewer safety failures

CardiaCures is developing
a multi-drug pipeline for atrial fibrillation with a
go-to-market in an inherited arrhythmia

Pipeline

Software-linked drugs

A new category of medicine.

Dosing software named in the FDA-approved label - developed, submitted, and reimbursed as a drug. Built with the people who helped write the regulatory science.

Explore the platform

Your Heart. Your Data. Your Cure.

Lifetime risk of atrial fibrillation is 1 in 3 over age 45 and its prevalence continues to increase globally